Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies.

Accumulation of insoluble alpha-synuclein aggregates in the brain is characteristic of Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. Although numerous studies on the aggregation properties of alpha-synuclein have been reported, little is known about its degradation so far. In view of proteolytic degradation, we have found that the serine protease neurosin (kallikrein-6) degrades alpha-synuclein and co-localizes with pathological inclusions such as Lewy bodies and glial cytoplasmic inclusions. In vitro study showed that neurosin prevented alpha-synuclein polymerization by reducing the amount of monomer and also by generating fragmented alpha-synucleins that themselves inhibited the polymerization. Upon cellular stress, neurosin was released from mitochondria to the cytosol, which resulted in the increase of degraded alpha-synuclein species. Down-regulation of neurosin caused accumulation of alpha-synuclein within cultured cells. Thus we concluded that neurosin plays a significant role in physiological alpha-synuclein degradation and also in the pathogenesis of synucleinopathies.

[1]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[2]  H. Zoghbi,et al.  Mouse and fly models of neurodegeneration. , 2002, Trends in genetics : TIG.

[3]  E. Masliah,et al.  Role of Cytochrome c as a Stimulator of α-Synuclein Aggregation in Lewy Body Disease* , 1999, The Journal of Biological Chemistry.

[4]  T. Tanaka,et al.  Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain. , 1997, Biochimica et biophysica acta.

[5]  G. Yousef,et al.  Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. , 2000, Clinical biochemistry.

[6]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[7]  Sid Gilman,et al.  Widespread Alterations of α-Synuclein in Multiple System Atrophy , 1999 .

[8]  J. Trojanowski,et al.  Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons , 2000, The Journal of Neuroscience.

[9]  W. Bender,et al.  A Drosophila model of Parkinson's disease , 2000, Nature.

[10]  J Q Trojanowski,et al.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. , 1998, The American journal of pathology.

[11]  G. Yousef,et al.  The Spectrum of Human Kallikrein 6 (Zyme/Protease M/Neurosin) Expression in Human Tissues as Assessed by Immunohistochemistry , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[12]  S Gilman,et al.  Widespread alterations of alpha-synuclein in multiple system atrophy. , 1999, The American journal of pathology.

[13]  L. Petrucelli,et al.  α-Synuclein Shares Physical and Functional Homology with 14-3-3 Proteins , 1999, The Journal of Neuroscience.

[14]  R A Crowther,et al.  Synthetic filaments assembled from C-terminally truncated alpha-synuclein. , 1998, FEBS letters.

[15]  R. Anthony Crowther,et al.  Synthetic filaments assembled from C‐terminally truncated α‐synuclein , 1998 .

[16]  P Choi,et al.  alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. , 1999, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[17]  R. Kopito,et al.  Aggresomes, inclusion bodies and protein aggregation. , 2000, Trends in cell biology.

[18]  M. Spillantini,et al.  α‐Synuclein metabolism and aggregation is linked to ubiquitin‐independent degradation by the proteasome , 2001, FEBS letters.

[19]  S. Mok,et al.  A Novel Protease Homolog Differentially Expressed in Breast and Ovarian Cancer , 1996, Molecular medicine.

[20]  E A Zemskov,et al.  Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. , 2001, Human molecular genetics.

[21]  M. Figueiredo-Pereira,et al.  Ubiquitin, cellular inclusions and their role in neurodegeneration , 1998, Trends in Neurosciences.

[22]  N. Bogdanovic,et al.  Expression of α-synuclein in the human brain: relation to Lewy body disease , 2001 .

[23]  D. Sulzer,et al.  Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. , 2000, Neuron.

[24]  I. Kanazawa,et al.  α‐Synuclein forms a complex with transcription factor Elk‐1 , 2001, Journal of neurochemistry.

[25]  S. Tsuji,et al.  Analysis of the expression level of α-synuclein mRNA using postmortem brain samples from pathologically confirmed cases of multiple system atrophy , 2001, Acta Neuropathologica.

[26]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[27]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[28]  P. Greengard,et al.  Synapsin I (Protein I), a nerve terminal-specific phosphoprotein. II. Its specific association with synaptic vesicles demonstrated by immunocytochemistry in agarose-embedded synaptosomes , 1983, The Journal of cell biology.

[29]  K. Arima,et al.  Immunoelectron-microscopic demonstration of NACP/α-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies , 1998, Brain Research.

[30]  N. Bogdanovic,et al.  Expression of alpha-synuclein in the human brain: relation to Lewy body disease. , 2001, Brain research. Molecular brain research.

[31]  Heidi Phillips,et al.  Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.

[32]  Shigeo Hirai,et al.  NACP/α-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy , 1998, Acta Neuropathologica.

[33]  P. Muchowski.  Protein Misfolding, Amyloid Formation, and Neurodegeneration A Critical Role for Molecular Chaperones? , 2002, Neuron.

[34]  R. Kopito,et al.  Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.

[35]  Pico Caroni,et al.  Neuropathology in Mice Expressing Human α-Synuclein , 2000, The Journal of Neuroscience.

[36]  J Q Trojanowski,et al.  Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α‐synuclein , 1998, Annals of neurology.

[37]  T. Chase,et al.  Degradation of α-Synuclein by Proteasome* , 1999, The Journal of Biological Chemistry.

[38]  P. Greengard,et al.  Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation , 1983, The Journal of cell biology.

[39]  P. Caroni,et al.  Neuropathology in mice expressing human alpha-synuclein. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[40]  C. Ross,et al.  Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. , 2001, Human molecular genetics.

[41]  Christian Haass,et al.  Subcellular Localization of Wild-Type and Parkinson's Disease-Associated Mutant α-Synuclein in Human and Transgenic Mouse Brain , 2000, The Journal of Neuroscience.

[42]  Makoto Hashimoto,et al.  Human recombinant NACP/α-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease , 1998, Brain Research.

[43]  J. Trojanowski,et al.  “Fatal Attractions” of Proteins: A Comprehensive Hypothetical Mechanism Underlying Alzheimer's Disease and Other Neurodegenerative Disorders , 2000, Annals of the New York Academy of Sciences.

[44]  K. Matsumoto,et al.  Protease M/neurosin mRNA is expressed in mature oligodendrocytes. , 1999, Brain research. Molecular brain research.

[45]  S W Scherer,et al.  Molecular characterization of zyme/protease M/neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease. , 1999, Genomics.

[46]  T Yamamoto,et al.  Localization of a novel type trypsin‐like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease , 2000, Psychiatry and clinical neurosciences.

[47]  I. Kanazawa,et al.  α-Synuclein Affects the MAPK Pathway and Accelerates Cell Death* , 2001, The Journal of Biological Chemistry.

[48]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[49]  K. Arima,et al.  NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. , 1998, Acta neuropathologica.

[50]  J. Trojanowski,et al.  Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. , 2000, The American journal of pathology.

[51]  R. Scheller,et al.  Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.